AMRI Announces New Hires and Promotions
Aside from recently announced new business deals, the company is also experiencing significant growth from within. The latest round of new hires and promotions are aimed at bolstering the company's leadership and technical capabilities, as well as aligning the company's sales and marketing initiatives.
To further strengthen AMRI’s integrated drug discovery biology and chemistry platform, AMRI hired Charles Jensen, Ph.D., as director of Drug Metabolism and Pharmacokinetics (DMPK) in September 2011. Dr. Jensen reports to Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery, and brings more than 20 years of relevant experience, working in the fields of drug metabolism and toxicology in the pharmaceutical industry. With experience in discovery and development phase DMPK, toxicology, and project management, Dr. Jensen strengthens AMRI's capabilities in the DMPK arena and further enhances our global platform of integrated discovery biology and chemistry services.
With the goal of bringing AMRI’s chemical manufacturing business in India to the next level, AMRI appointed Mr. Subramanyam Maddala as President, India Operations, in October 2011. Reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI, Mr. Maddala leads AMRI’s Indian API manufacturing operations and has responsibility for AMRI facility operations in Hyderabad and Aurangabad, India. Mr. Maddala brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. In addition, AMRI welcomed Rajesh Shenoy, Ph.D., back to the United States to assume the position of Director of Project Management-Pharmaceutical Services, from his role of Managing director, AMRI India. Dr. Shenoy continues to report to Dr. Hagen, and now has full leadership responsibilities for AMRI’s global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish. Dr. Shenoy has been with AMRI since 1998.
With the goal of bringing senior-level in vitro biology expertise to AMRI's Singapore site, the company announced a key addition to the management team at its Singapore location in April 2012. Saravanakumar Dhakshinamoorthy, Ph.D. joined AMRI’s Singapore site as Director of In Vitro Biology, reporting to Takeshi Yura, Ph.D., Senior Director, AMRI Singapore. As the leader of AMRI’s biology resources and staff in Singapore, Dr. Dhakshinamoorthy and his team will be working closely with on-site colleagues supporting customer projects as well as in collaboration with AMRI’s U.S.-based biology and DMPK teams.
In February 2012, AMRI expanded its quality control leadership to support future growth with the hire of Tom McGrath as Director, Quality for Aseptic Services at AMRI’s Burlington, Mass. site. The appointment of Mr. McGrath demonstrates AMRI’s commitment to providing industry leading aseptic services with uncompromising quality to the company’s growing client base. He reports to Junan Guo, Ph.D., Senior Director, Pharmaceutical and Quality Services, and brings more than 15 years of quality systems and quality control experience in the pharmaceutical industry, which will strengthen AMRI’s capabilities in this technically complex area. Also at AMRI’s Burlington site, Stephen Rossmeisl joined the company as Senior Facilities Manager in March 2012. Mr. Rossmeisl’s experience with critical cleanroom equipment, utilities and systems will strengthen AMRI’s ability to meet the growing needs of its customers as the level of activity of new business at Burlington continues on a path to a return to previously robust levels.
AMRI has also moved to strengthen its Business Development and Marketing teams with promotions, a new structure, and the hiring of an external marketing agency. These moves create a seamless integration of our business development and marketing efforts with the goal of optimizing territory cross-selling opportunities and customer service.
Related to this business move, AMRI’s North American Discovery and Development business development teams have been combined into one functional sales organization under Christopher Conway, who has been promoted to Vice President, Business Development, North America. In a separate organizational change, marketing and communications now reports to Louis Garguilo, who was promoted to Vice President, Business Development. In Louis’ expanded role, he will continue to lead AMRI’s sales efforts in the Japan and Asia-Pacific markets while overseeing marketing and communications activities as AMRI rolls out its rebranding campaign.
AMRI recently announced in May that William S. Marth has joined its Board of Directors. Mr. Marth has served as President and Chief Executive Officer – Americas, Teva, since June 2010, after serving as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and as President and Chief Executive Officer of Teva USA from January 2005 to January 2008. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.